Neurological Sciences

, Volume 34, Issue 2, pp 225–229 | Cite as

Effects of topiramate use on body composition and resting metabolic rate in migraine patients

  • Mehmet Yaman
  • Kagan Ucok
  • Hayri Demirbas
  • Abdurrahman Genc
  • Serdar Oruc
  • Hatice Karabacak
  • Gokhan Koyuncu
Original Article
First Online:
Received:
Accepted:

Abstract

Topiramate is an anticonvulsant agent effective in the prophylaxis of migraine, which also induces weight reduction by an unknown mechanism. We investigated the effect of topiramate on resting metabolic rate, anthropometric measurements, and body composition in patients with migraine independently from any intention to lose body weight. Forty patients (18–71 years old) with migraine were treated with 100 mg of topiramate/day over a period of 3 months. Anthropometric measurements, body fat proportions and resting metabolic rates of these patients were measured before and after treatment. At the end of 3 months, we detected mean 0.8 kg reduction in body weight and 0.3 kg/m2 reduction in body mass index (BMI). Waist circumference decreased significantly (p = 0.01). Body fat ratio decreased (p = 0.016). Abdominal skinfold measurements decreased after treatment (p = 0.048); however, no difference was found in other regions (p > 0.05). We did not find a significant difference in resting metabolic rate (p > 0.05).These TPM-treated patients lost weight and had reduction in their mean BMI. It was seen that patients lost weight from body fat tissue and central area. We saw that TPM’S weight-reducing effect was independent from resting metaobolic rate. The weight-reducing effect of TPM may result from changes on the hypothalamus.

Keywords

Resting metabolic rate Weight loss Body composition Topiramate Migraine 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Alberici A, Borroni B, Manelli F, Griffini S, Zavarise P, Padovani A, Volta GD (2009) Topiramate weight loss in migraine patients. J Neurol Sci 278:64–65PubMedCrossRefGoogle Scholar
  2. 2.
    Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, quality of life, and depression: a population-based case control study. Neurology 55:629–635PubMedCrossRefGoogle Scholar
  3. 3.
    Lipton RB, Bigal ME, Rush SR, Yenkosky JP, Libarman JN, Bartleson JD (2004) Migraine practice parameters among neurologist. Neurology 62:1926–1931PubMedCrossRefGoogle Scholar
  4. 4.
    Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J (2006) Long-term migraine prevention with toiramate: open label extension of pivotal trials. Headache 46:1151–1160PubMedCrossRefGoogle Scholar
  5. 5.
    Silberstein SD (2005) Topiramate in migraine prevention. Headache 45(Suppl 1):57–65CrossRefGoogle Scholar
  6. 6.
    Kocer A, Dikici S, Atakay S, Okuyucu Ş (2007) Serum uric acid and lpid levels while taking topiramate for migraine. Headache 48:1056–1060PubMedGoogle Scholar
  7. 7.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11:722–733PubMedCrossRefGoogle Scholar
  8. 8.
    Tremblay A, Chaput JP, Berube-Parent S, Prud’homme D, Leblanc C, Almeras N et al (2007) The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 63:123–134PubMedCrossRefGoogle Scholar
  9. 9.
    Vogels N, Diepvens K, Westerterp-Plantenga MS (2005) Predictors of long-term weight maintenance. Obes Res 13:2162–2168PubMedCrossRefGoogle Scholar
  10. 10.
    International classification of headache disorders, 2nd edition. Headache Classification Subcommittee of the International Headache Society (2004). Cephalalgia24(Suppl 1):8–152Google Scholar
  11. 11.
    American College of Sports Medicine (2006) ACSM’s health-related physical fitness assessment manual. 2nd edn. Lippincott Williams & Wilkins, USA, pp 48–49Google Scholar
  12. 12.
    Heyward VH (2006) Advanced fitness assessment and exercise prescription, 5th edn. Human Kinetics, USA 337Google Scholar
  13. 13.
    Ucok K, Aycicek A, Sezer M, Genc A, Akkaya M, Caglar V, Fidan F, Unlu M (2009) Aerobic and anaerobic exercise capacities in obstructive sleep apnea and associations with subcutaneous fat distributions. Lung 187:29–36PubMedCrossRefGoogle Scholar
  14. 14.
    Ucok K, Aycicek A, Sezer M, Fidan F, Akgun L, Akkaya M, Unlu M (2011) Resting metabolic rate and anthropometric measurements in male sleep apnea patients. Intern Med 50:833–838PubMedCrossRefGoogle Scholar
  15. 15.
    Peterlin BL, Alexander G, Tabby D, Reichenberger E (2008) Oligomerization state-dependent elevations of adiponectin in chronic daily headache. Neurology 70:1905–1911PubMedCrossRefGoogle Scholar
  16. 16.
    Peterlin BL, Rosso AL, Rapoport AM, Scher AI (2010) Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache 50:52–62PubMedCrossRefGoogle Scholar
  17. 17.
    Peterlin BL, Rapoport AM, Kurth T (2010) Migraine and obesity: epidemiology, mechanisms, and implications. Headache 50:631–648PubMedCrossRefGoogle Scholar
  18. 18.
    Verrotti A, Scaparotto A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S (2011) Topiramate-induced weight loss: a review. Epilepsy Res 95:189–199PubMedCrossRefGoogle Scholar
  19. 19.
    Kirov G, Treget J (2005) Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series. BMC Psychiatry 7:5–19Google Scholar
  20. 20.
    Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC (2007) Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin pharmacol 14:234–239Google Scholar
  21. 21.
    Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U (2007) Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes 31:1140–1147CrossRefGoogle Scholar
  22. 22.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH for the U.S (2003) Topiramate research group. Obes Res 11:722–733Google Scholar
  23. 23.
    Schütt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C (2010) Weight reducing and metabolic effects of topiramate in patients with migraine-an observational study. Exp Clin Endocrinal Diabetes 118:449–452CrossRefGoogle Scholar
  24. 24.
    Liang Y, She P, Wang X, Demarest K (2006) The Messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 55:1411–1419PubMedCrossRefGoogle Scholar
  25. 25.
    York DA, Singer L, Thomas S, Bray GA (2000) Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16:967–975PubMedCrossRefGoogle Scholar
  26. 26.
    Sachdeo RC, Glauser TA, Ritter F et al, Topiramate YL study group (1999) A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology 52:1882–1887Google Scholar
  27. 27.
    Ben-Menachem E, Axelsen M, Johanson EH et al (2003) Predictors of weight loss in adults with topiramate treated epilepsy. Obes Res 11:556–562PubMedCrossRefGoogle Scholar
  28. 28.
    Li HF, Zou Y, Xia ZZ et al (2009) Effects of topiramate on weight and metobolism in children with epilepsy. Acta Paedìatr 98:1521–1525PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Mehmet Yaman
    • 1
  • Kagan Ucok
    • 2
  • Hayri Demirbas
    • 1
  • Abdurrahman Genc
    • 2
  • Serdar Oruc
    • 1
  • Hatice Karabacak
    • 2
  • Gokhan Koyuncu
    • 1
  1. 1.Department of Neurology, Faculty of MedicineAfyon Kocatepe UniversityAfyonkarahisarTurkey
  2. 2.Department of Physiology, Faculty of MedicineAfyon Kocatepe UniversityAfyonkarahisarTurkey

Personalised recommendations